Search - tctmd.com

Displaying 1 - 20 of 1081

Sort: Relevancy | Date

GoFreshRx, THRIVE Trials Show BP Benefits of ‘Food as Medicine’

News Conference News ACC 2026

GoFreshRx, THRIVE Trials Show BP Benefits of ‘Food as Medicine’

March 31, 2026

SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF

News Conference News ACC 2026

SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF

March 29, 2026

US Societies Lay Out Requirements for Transcatheter Tricuspid Valve Procedures

News Daily News

US Societies Lay Out Requirements for Transcatheter Tricuspid Valve Procedures

Michael O'Riordan

March 27, 2026

Genomics, Lipids, Inflammation at Midlife Predict Future CAD

News Daily News

Genomics, Lipids, Inflammation at Midlife Predict Future CAD

March 25, 2026

Apixaban Bests Rivaroxaban for Bleeding in VTE: COBRRA

News Daily News

Apixaban Bests Rivaroxaban for Bleeding in VTE: COBRRA

Yael L. Maxwell

March 16, 2026

Presentation THT 2026

The Effects Of Istaroxime In Patients With Acute Heart Failure (AHF) And Cardiogenic Shock (CS) – Combined Analysis Of 5 Phase 2 Placebo Controlled Clinical Trials

Presenter: Beth A. Davison

March 04, 2026

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

News Daily News

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

Michael O'Riordan

March 03, 2026

Presentation THT 2026

LVAD Combined with hiPSC-Cardiomyocyte Transplantation for Advanced Heart Failure: Preliminary Safety and Functional Recovery Results from a Randomized Trial

Presenter: yongfeng Shao

March 03, 2026

AVR in Asymptomatic AS: Look to the ‘Sweet Spot’ for Timing

News Conference News EAPCI 2026

AVR in Asymptomatic AS: Look to the ‘Sweet Spot’ for Timing

February 25, 2026

Baduanjin, a Traditional Chinese Practice, Lowers BP

News Daily News

Baduanjin, a Traditional Chinese Practice, Lowers BP

February 20, 2026

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

February 02, 2026

Periprocedural MI Signals Worse Outcomes in Stented NSTE ACS Patients: MATRIX

News Daily News

Periprocedural MI Signals Worse Outcomes in Stented NSTE ACS Patients: MATRIX

Michael O'Riordan

January 15, 2026

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

Year in Review: Reimbursement, Funding Cuts Mark Top Policy & Practice News

News Daily News

Year in Review: Reimbursement, Funding Cuts Mark Top Policy & Practice News

Yael L. Maxwell

December 26, 2025

Remission From Prediabetes Halves CV Risk: Registry Data

News Daily News

Remission From Prediabetes Halves CV Risk: Registry Data

Yael L. Maxwell

December 19, 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

TAVI Patients Seem to Pay No Penalty for Obstructive CAD

News Daily News

TAVI Patients Seem to Pay No Penalty for Obstructive CAD

Yael L. Maxwell

December 09, 2025

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

News Daily News

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

November 24, 2025

Long-Awaited CREST-2 Results Bolster Stents for Asymptomatic Carotid Stenosis

News Daily News

Long-Awaited CREST-2 Results Bolster Stents for Asymptomatic Carotid Stenosis

November 21, 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.